The world of Good Distribution Practice (GDP) has developed significantly over the past few years. There has been an increase in focus from many regulatory agencies including the MHRA. With Brexit still highly on the agenda, the result of the Brexit deal will undoubtedly have an impact on supply chains for pharmaceutical products sourced from the European Union and European Economic Area. The MHRA published guidance last year to clarify and support the pharmaceutical industry and importers in the UK. RSSL recognises that there is a need to do more to assist industry in creating an environment that supports the role and responsibilities of Responsible Persons for GDP, Logistic Managers and other individuals involved in the pharmaceutical supply chain industry.